NPPA Cancer Drug Pricing: The 30% Trade Margin Cap Explained

Overview

The National Pharmaceutical Pricing Authority approved an in-principle thirty percent cap on trade margins for non-scheduled anti-cancer drugs under Paragraph 19 of the DPCO 2013. The intervention reins in retail markups. Historically, these markups escalate up to seven hundred percent.

This statutory formula caps the commercial spread between the manufacturer's Price to Stockist and the Maximum Retail Price. Yet downstream limits solve only half the problem. Without base-cost audits and curbs on captive hospital dispensing networks, pharmaceutical manufacturers can evade limits by artificially inflating wholesale transfer prices.

As of October 2026, the National Pharmaceutical Pricing Authority approved an in-principle thirty percent trade margin cap on non-scheduled anti-cancer medicines under Paragraph 19 of the DPCO 2013. The decision emerged from the 151st Authority meeting convened by the drug pricing regulator.

Two core administrative steps underpin this emergency intervention:

• Statutory trigger: The Central Government acted under Paragraph 19 of the Drugs (Prices Control) Order, 2013. This power allows price revisions under extraordinary circumstances in public interest, bypassing routine regulatory schedules.
• Expert review: An expert panel under the Directorate General of Health Services received a mandate to submit its formal report by October 14, 2026. The committee was tasked with selecting more non-scheduled oncology formulations for the 30% ceiling.

The Pronab Sen Task Force on Price Control of Drugs first conceptualised Trade Margin Rationalisation (TMR) in 2005 as a market-friendly alternative to statutory price caps. The committee recommended capping intermediary spreads across wholesale and retail tiers rather than fixing uniform production prices.

In February 2019, the Department of Pharmaceuticals operationalised this approach through Gazette Notification S.O. 1041(E). The pilot generated measurable consumer relief across outpatient oncology channels:

• Wide brand coverage: Capped margins at 30% across 42 non-scheduled oncology formulations spanning 526 distinct commercial brands.
• Steep price cuts: Retail prices dropped by up to ninety-one percent, recording an average price reduction of roughly fifty percent.
• Household savings: Delivered recurring annual consumer savings of ₹984 crore across covered therapies.
• Supply preservation: Regulators invoked Paragraph 21(2) of the DPCO 2013, compelling manufacturers to maintain existing production levels and prevent artificial shortages.

The National Pharmaceutical Pricing Authority calculates permissible retail prices using the formula notified in Gazette Notification S.O. 1041(E). The regulatory formula determines the Maximum Retail Price directly from the Price to Stockist (PTS):

Permissible Retail Price = Price to Stockist × (1 + (Trade Margin / (100 - Trade Margin)))

Under this statutory formula, Trade Margin is strictly capped at thirty percent of the final consumer price. Setting the trade margin at thirty percent creates an allowable mathematical multiplier of roughly 1.428 over the base PTS.

Department of Pharmaceuticals briefings revealed that non-scheduled cancer medicines historically carried average markups of 170%, with severe instances escalating past seven hundred percent. Commercial distributors and hospital pharmacies exploited this gap to capture wide margins.

The Parliamentary Standing Committee on Chemicals and Fertilizers warned in August 2026 that pharmaceutical firms can defeat trade margin caps by manipulating base wholesale figures. Because the mechanism restricts only the commercial percentage spread, drugmakers retain the incentive to artificially raise baseline PTS.

This pricing vulnerability stems from clear regulatory loopholes:

• Transfer price gaming: A firm facing a compressed thirty percent distribution markup can increase its wholesale billing price to stockists. This accounting manoeuvre protects revenue for both the manufacturer and favoured hospital distributors.
• Unregulated entry rates: Under Paragraph 20 of DPCO 2013, non-scheduled formulations face an annual ten percent ceiling on price hikes. However, their initial launch prices remain completely unregulated without Paragraph 19 intervention.
• Lack of cost oversight: The Parliamentary Standing Committee urged the Department of Pharmaceuticals to institute backward cost audits. Such audits verify actual production and import expenses to prevent inflated wholesale baselines.

The Competition Commission of India observed that private hospitals operate captive dispensing networks insulated from standard market competition. Inpatient hospital environments spur brand competition over price competition, prompting healthcare providers to stock high-margin formulations.

Distortions within private hospital distribution centre on three main practices:

• Tied clinical services: Hospitals bundle oncology treatments with exclusive internal pharmacy dispensing, barring patients from buying cheaper alternatives outside.
• Inelastic demand: Patients undergoing intensive chemotherapy cannot negotiate prescription costs or challenge administrative restrictions.
• Prescription controls: The National Medical Commission introduced rules requiring practitioners to prescribe generic pharmacological names instead of commercial brands, enabling retail substitution.

The Drugs (Prices Control) Order, 2013 establishes two distinct regulatory techniques to curb runaway pharmaceutical expenditure across domestic healthcare markets. Routine price regulation governs scheduled essential drugs, while Trade Margin Rationalisation provides a flexible tool for non-scheduled therapies.

The standard framework covers medicines listed under the National List of Essential Medicines (NLEM). Under Paragraph 4 of DPCO 2013, the pricing authority calculates a uniform national ceiling price based on the simple average market price of all brands holding at least one percent market share. In contrast, Trade Margin Rationalisation establishes enterprise-specific maximum prices anchored directly to each company's reported Price to Stockist.

In Paschim Banga Khet Mazdoor Samity (1996), the Supreme Court of India ruled that the duty to protect life under Article 21 requires accessible medical care. The bench affirmed that the constitutional obligation of the State includes providing timely treatment, making financial affordability an integral component of the right to health.

Two contrasting priorities define this ongoing debate:

• Household vulnerability: National Health Accounts Estimates for 2020-21 show that Out-of-Pocket Expenditure (OOPE) represents 39.4% of Total Health Expenditure in India. Retail purchases of medicines remain the primary driver of catastrophic debt.
• Commercial claims vs intermediary capture: Drugmakers argue that high margins fund research and development. However, excessive retail markups captured by hospital pharmacies reward intermediaries rather than clinical innovation.

The Parliamentary Standing Committee on Chemicals and Fertilizers recommended that the Department of Pharmaceuticals incorporate permanent enabling statutory provisions for Trade Margin Rationalisation directly into the DPCO 2013. Amending the statutory order provides predictable regulatory oversight, replacing periodic invocations of Paragraph 19.

Public health procurement agencies provide a proven mechanism to bypass exploitative distribution chains. Transparent state bodies like the Tamil Nadu Medical Services Corporation and Rajasthan Medical Services Corporation secure sixty to ninety percent price cuts on oncology molecules relative to commercial retail prices. Adopting pooled procurement at the national level provides strong bargaining leverage against international pharmaceutical monopolies.

Sustained administrative coordination must reinforce these procurement mechanisms:

1. Conduct mandatory backward cost audits on baseline Price to Stockist submissions to prevent artificial wholesale price padding.
2. Enforce National Medical Commission directives requiring generic prescribing to break captive hospital dispensing monopolies.
3. Direct the Competition Commission of India to penalise hospital chains that condition clinical treatment on buying from in-house dispensaries.
4. Mandate public disclosures of wholesale transfer prices across commercial oncology distributors to ensure market transparency.

• The National Pharmaceutical Pricing Authority approved an in-principle thirty percent trade margin cap on non-scheduled oncology drugs under Paragraph 19 of the DPCO 2013.
• Trade Margin Rationalisation traces its policy origin to the 2005 Pronab Sen Committee, offering a market-pegged alternative to rigid administrative price ceilings.
• The 2019 pilot across 42 cancer medicines proved effective, generating annual consumer savings of ₹984 crore with average price drops of fifty percent.
• Manufacturers can evade retail margin controls by artificially inflating baseline PTS, demanding statutory backward cost audits to preserve consumer relief.
• The Competition Commission of India identified captive hospital pharmacies as major market bottlenecks, urging open procurement and generic substitution.